個股熱度排行 | 8月10日港股盤前
根據uSMART輿情監測數據，從9日晚間到10日港股盤前時間段，市場關注指數最高的5只股票是聯想集團、白雲山、名創優品、再鼎醫藥-B、永利澳門。
8月10日—港股關注排行TOP5
聯想集團
關注度第一爲聯想集團，該股上個交易日收盤下跌0.98%，報於7.05港元。近5個交易日累計上漲0.28%。在消息面和社交媒體方面，輿情以看多爲主。較被市場關注的消息有：
PC之外業務佔比達到37%，聯想集團迎來“第二增長曲線”裏程碑
聯想集團一季度溢利5.16億美元 同比增長11%
白雲山
關注度第二爲白雲山，該股上個交易日收盤上漲2.00%，報於20.40港元。近5個交易日累計上漲2.31%。在消息面和社交媒體方面，輿情以看空爲主。較被市場關注的消息有：
白雲山：3家子公司就虛增原料藥價格、虛擡藥價套取資金遭醫保局通報
國家醫保局通報對白雲山旗下3家企業調查結果：虛擡87種藥品價格，套取資金用作商業行賄
名創優品
關注度第三爲名創優品，該股上個交易日收盤上漲1.24%，報於13.02港元。近5個交易日累計上漲11.09%。在消息面和社交媒體方面，輿情以看空爲主。較被市場關注的消息有：
熱門中概股週二收盤普遍走低 智富融資暴跌超89% 尚乘數科跌超47% 名創優品跌6%
#名創優品致歉聲明#衝上熱搜 網友：又一個假洋鬼子翻車了
再鼎醫藥-B
關注度第四爲再鼎醫藥-B，該股上個交易日收盤上漲6.52%，報於37.60港元。近5個交易日累計上漲24.09%。在消息面和社交媒體方面，輿情以看空爲主。較被市場關注的消息有：
再鼎醫藥上季虧損減少至約1.4億美元 公司：爭取將擎樂和紐再樂納入國家醫保藥品目錄
再鼎醫藥次季虧損收窄至1.38億元美元 收入增30.4%
永利澳門
關注度第五爲永利澳門，該股上個交易日收盤下跌0.81%，報於4.91港元。近5個交易日累計下跌0.41%。在消息面和社交媒體方面，輿情以看空爲主。較被市場關注的消息有：
永利澳門發佈第二季業績 擁有人應佔虧損淨額約2.71億美元 同比擴大約1.32倍
永利澳門次季虧損擴大至2.71億美元 總收益減少74.2%
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
